On October 14, 2024, Merck and Exelixis announced a development collaboration to study Exelixis' investigational drug zanzalintinib in combination with Merck's cancer drugs, Keytruda and Welireg.
The agreement includes a Phase 3 pivotal study of zanzalintinib with Keytruda for head and neck squamous cell carcinoma. Additionally, a Phase 1/2 trial and two Phase 3 studies are planned for zanzalintinib in combination with Welireg for renal cell carcinoma.
Exelixis will retain all global commercial and marketing rights to zanzalintinib, which is being developed for advanced solid tumors. This collaboration allows Merck to explore new combination therapies and expand the potential utility of its existing oncology portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.